reports
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Finan...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th,...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financ...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), ...
scPharmaceuticals Announces Participation in Two Upcoming Investor Con...
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences: 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.Leerink Partners 2025 Global Healthcare Conference: Corporate pre...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET. A webcast of the presentation can be accessed or under “News & Events” in the Invest...
- Dave Nicoski
- Ross LaDuke
TWI TITAN INTERNATIONAL INC.
TRIP TRIPADVISOR INC.
TITN TITAN MACHINERY
SLP SIMULATIONS PLUS
RYI RYERSON HOLDING CORPORATION
QCOM QUALCOMM INC
PCRX PACIRA BIOSCIENCES INC.
MOS MOSAIC COMPANY
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
IVZ INVESCO LTD.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
DLTR DOLLAR TREE INC.
DDD 3D SYSTEMS CORPORATION
CERS CERUS CORP.
AVD AMERICAN VANGUARD
ANIP ANI PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
UPS UNITED PARCEL SERVICE INC. CLASS B
OSTK OVERSTOCK.COM INC.
GDEN GOLDEN ENTERTAINMENT
FRX_CN FENNEC PHARMACEUTICALS
ODEL.N0000 ODEL PLC
BRKS BROOKS AUTOMATION INC.
CCV COUNTERPATH
TDC TERADATA CORPORATION
BHF BRIGHTHOUSE FINANCIAL INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
SIBN SI-BONE
PINS PINTEREST INC. CLASS A
VIAC VIACOMCBS INC. CLASS B
ORIC ORIC PHARMACEUTICALS
THRY THRYV HOLDINGS
CERT CERTARA
ONTF ON24
SMTI SANARA MEDTECH
SDGR SCHRODINGER
COUR COURSERA INC
BBWI BATH & BODY WORKS INC
DH DEFINITIVE HEALTHCARE CORP
VERV VERVE THERAPEUTICS INC
PTLO PORTILLOS INC
DCGO DOCGO INC
EHAB ENHABIT INC
SVV SAVERS VALUE VILLAGE INC
QIPT PATIENT HOME MONITORING CORP
HUM HAMILTON U.S. MID-CAP FINANCIALS ETF
CXM SPRINKLR INC
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500, Nasdaq 100 Testing Bull Flag Supports Continued strong economic data has reduced the number of expected Fed rate cuts, which has pushed long-term Treasury bond yields and the U.S. dollar (DXY) above some key levels, putting some pressure on the broad market indexes. The Bloomberg Commodity index (DJP) is breaking above the key $33.25 resistance level, while WTI crude oil is breaking above its 1+ year downtrend. Upside is likely to be capped due to these concerns, but we still continue ...
GBX GREENBRIER COMPANIES INC.
AAL AMERICAN AIRLINES GROUP INC.
ET ENERGY TRANSFER L.P.
GATX GATX CORPORATION
RAIL FREIGHTCAR AMERICA INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
FSTR L.B. FOSTER CO.
SMC SUMMIT MIDSTREAM CORPORATION
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Fu...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE N...
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results an...
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, N...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on ...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the thi...
- Gary Brode
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October ...
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on a nephrologis...
- Gary Brode
- Jonathan Moreland
UEC URANIUM ENERGY CORP
PSEC PROSPECT CAPITAL CORPORATION
PENN PENN NATIONAL GAMING INC.
PBF PBF ENERGY INC. CLASS A
OOMA OOMA
LANC LANCASTER COLONY CORPORATION
IMMR IMMERSION CORP.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
CGNX COGNEX CORPORATION
CECE CECO ENVIRONMENTAL CORP.
DKL DELEK LOGISTICS PARTNERS
MYRG MYR GROUP INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
CIA CITIZENS INC. CL A
BRN BARNWELL INDUSTRIES
CNX CONSOL ENERGY INC.
TALO TALOS ENERGY INC.
ISDR ISSUER DIRECT CORP.
ESTC ELASTIC N.V.
CRTX CORTEXYME
ONEW ONEWATER MARINE
HPK HIGHPEAK ENERGY INC (A)
ABCL ABCELLERA BIOLOGICS
LESL LESLIES
BFLY BUTTERFLY NETWORK INC (A)
INBX INHIBRX
NN INC.
AMLX NEXTNAV INC
NXGL AMYLYX PHARMACEUTICALS INC
HR NEXGEL INC
VFC HEALTHCARE TRUST OF AMERICA INC.
CALC VF CORPORATION
SMRT CALCIMEDICA INC.
ATMU SMARTRENT INC
STCN ATMUS FILTRATION TECHNOLOGIES INC
SRBK STEEL CONNECT INC
LIFW SR BANCORP INC
DBD MSP RECOVERY INC.
SUNS DIEBOLD NIXDORF INCORPORATED
MSGE SUNRISE REALTY TRUST
XPER MSG ENTERTAINMENT SPINCO
NUTX INC.
OBDE XPERI INC
LOCO NUTEX HEALTH INC
NTG OWL ROCK CAPITAL CORP III
MRAI LOVE OIL INC.
MDRR TORTOISE MIDSTREAM ENERGY FUND INC
GDV MARPAI
INC.
MEDALIST DIVERSIFIED REIT INC.
THE GABELLI DIVIDEND & INCOME TRUST
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global...
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also ...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
PBF PBF ENERGY INC. CLASS A
OOMA OOMA
MPAA MOTORCAR PARTS OF AMERICA INC.
LANC LANCASTER COLONY CORPORATION
IMMR IMMERSION CORP.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CRK COMSTOCK RESOURCES INC.
BEN FRANKLIN RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
ATEC ALPHATEC HOLDINGS INC.
DKL DELEK LOGISTICS PARTNERS
MYRG MYR GROUP INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
GBDC GOLUB CAPITAL BDC INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
APPN APPIAN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ISDR ISSUER DIRECT CORP.
AXR AMREP
ELAN ELANCO ANIMAL HEALTH INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
GRWG GROWGENERATION
ONEW ONEWATER MARINE
BILL BILL.COM HOLDINGS
HPK HIGHPEAK ENERGY INC (A)
ABCL ABCELLERA BIOLOGICS
LESL LESLIES
BFLY BUTTERFLY NETWORK INC (A)
INBX INHIBRX
IMMX INC.
NN IMMIX BIOPHARMA INC
NXGL NEXTNAV INC
BIGZ NEXGEL INC
PFHC BLACKROCK INNOVATION AND GROWTH TST
CALC PROFRAC HLDG CORP
ATMU CALCIMEDICA INC.
ET ATMUS FILTRATION TECHNOLOGIES INC
MIO ENERGY TRANSFER LP
PEO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
SUNS PETROLEUM & RESOURCES CORPORATION
XPER SUNRISE REALTY TRUST
OBDE XPERI INC
LOCO OWL ROCK CAPITAL CORP III
LOVE OIL INC.
- Jonathan Moreland
OOMA OOMA
CRK COMSTOCK RESOURCES INC.
WY WEYERHAEUSER COMPANY
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EB EVENTBRITE
FSLY FASTLY
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
U UNITY SOFTWARE INC.
FTCI FTC SOLAR
HYZN INC.
NN HYZON MOTORS INC.
NXGL NEXTNAV INC
BIGZ NEXGEL INC
GNLX BLACKROCK INNOVATION AND GROWTH TST
ATMU GENELUX CORP
DBD ATMUS FILTRATION TECHNOLOGIES INC
MIO DIEBOLD NIXDORF INCORPORATED
PEO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
SUNS PETROLEUM & RESOURCES CORPORATION
OBDE SUNRISE REALTY TRUST
LOCO OWL ROCK CAPITAL CORP III
LOVE OIL INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.